Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
| Autor: | Joel A. Malek, Hiam Chemaitelly, Gheyath K. Nasrallah, Einas Al Kuwari, Anvar Hassan Kaleeckal, Hadi M. Yassine, Hamad Eid Al Romaihi, Abdullatif Al Khal, Hanan F. Abdul Rahim, Riyazuddin Mohammad Shaik, Patrick Tang, Zaina Al Kanaani, Roberto Bertollini, Laith J. Abu-Raddad, Fatiha M. Benslimane, Mohamed Ghaith Al Kuwari, Adeel A. Butt, Andrew Jeremijenko, Ali Nizar Latif, Hebah A. Al Khatib, Mohamed H. Al-Thani, Peter Coyle, Houssein H. Ayoub |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak delta variant COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Disease vaccine Epidemiology case–control beta variant Medicine Humans RNA Messenger BNT162 Vaccine Messenger RNA business.industry SARS-CoV-2 COVID-19 General Medicine one dose Virology infection alpha variant variant B1.617.2 epidemiology B1.1.7 business AcademicSubjects/MED00295 Rapid Communication |
| Zdroj: | Abu-Raddad, L J, Chemaitelly, H, Yassine, H M, Benslimane, F M, Al Khatib, H A, Tang, P, Malek, J A, Coyle, P, Ayoub, H H, Al Kanaani, Z, Al Kuwari, E, Jeremijenko, A, Kaleeckal, A H, Latif, A N, Shaik, R M, Abdul Rahim, H F, Nasrallah, G K, Al Kuwari, M G, Al Romaihi, H E, Al-Thani, M H, Al Khal, A, Butt, A A & Bertollini, R 2021, ' Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses ', Journal of Travel Medicine, vol. 28, no. 7 . https://doi.org/10.1093/jtm/taab083 Journal of Travel Medicine |
| ISSN: | 1195-1982 |
| Popis: | Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week-by-week after the first dose. 75% of protection against infection and disease is reached 15-21 daysafter the first dose. Protection increased most rapidly against hospitalization and death and slowest against B.1.351infection.While protection of one dose beyond 21 days could not be assessed, findings support delaying the second vaccinedosein situations of limited vaccine suppliesand high incidences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|